用于治疗宫颈癌的血管生成抑制剂的药代动力学和药效学：现状与未来。

IF 3.9 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2024-09-09 DOI:10.1080/17425255.2024.2401586

Aurora Gonzalez-Fierro,Guadalupe Domínguez-Gómez,Alma Chavez-Blanco,Alfonso Duenas-Gonzalez

{"title":"用于治疗宫颈癌的血管生成抑制剂的药代动力学和药效学：现状与未来。","authors":"Aurora Gonzalez-Fierro,Guadalupe Domínguez-Gómez,Alma Chavez-Blanco,Alfonso Duenas-Gonzalez","doi":"10.1080/17425255.2024.2401586","DOIUrl":null,"url":null,"abstract":"INTRODUCTION\r\nThe treatment of advanced cervical cancer is continuously developing. There is a critical need to explore new treatment options to improve cure rates and make treatment more affordable. Despite efforts in prevention, cervical cancer remains the fourth most common cancer worldwide in terms of both incidence and mortality.\r\n\r\nAREAS COVERED\r\nThis article offers an updated and critical analysis of angiogenesis inhibitors used in the treatment of advanced cervical cancer. It should be noted that this is not a systematic review.\r\n\r\nEXPERT OPINION\r\nBevacizumab is currently the primary antiangiogenic agent used alongside chemotherapy and has become the standard of care for advanced cervical cancer. However, there are still uncertainties regarding the molecular mechanisms and associations in cervical cancer that could help in optimizing the use of Bevacizumab. Factors such as cost, toxicity, and methodological issues in the GOG-240 trial must be considered.","PeriodicalId":12250,"journal":{"name":"Expert Opinion on Drug Metabolism & Toxicology","volume":"21 1","pages":"1-9"},"PeriodicalIF":3.9000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future.\",\"authors\":\"Aurora Gonzalez-Fierro,Guadalupe Domínguez-Gómez,Alma Chavez-Blanco,Alfonso Duenas-Gonzalez\",\"doi\":\"10.1080/17425255.2024.2401586\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"INTRODUCTION\\r\\nThe treatment of advanced cervical cancer is continuously developing. There is a critical need to explore new treatment options to improve cure rates and make treatment more affordable. Despite efforts in prevention, cervical cancer remains the fourth most common cancer worldwide in terms of both incidence and mortality.\\r\\n\\r\\nAREAS COVERED\\r\\nThis article offers an updated and critical analysis of angiogenesis inhibitors used in the treatment of advanced cervical cancer. It should be noted that this is not a systematic review.\\r\\n\\r\\nEXPERT OPINION\\r\\nBevacizumab is currently the primary antiangiogenic agent used alongside chemotherapy and has become the standard of care for advanced cervical cancer. However, there are still uncertainties regarding the molecular mechanisms and associations in cervical cancer that could help in optimizing the use of Bevacizumab. Factors such as cost, toxicity, and methodological issues in the GOG-240 trial must be considered.\",\"PeriodicalId\":12250,\"journal\":{\"name\":\"Expert Opinion on Drug Metabolism & Toxicology\",\"volume\":\"21 1\",\"pages\":\"1-9\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Drug Metabolism & Toxicology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17425255.2024.2401586\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Metabolism & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17425255.2024.2401586","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

简介：晚期宫颈癌的治疗方法在不断发展。目前亟需探索新的治疗方案，以提高治愈率并使治疗费用更加低廉。尽管在预防方面做出了努力，但就发病率和死亡率而言，宫颈癌仍是全球第四大常见癌症。专家观点贝伐单抗是目前与化疗同时使用的主要抗血管生成药物，已成为治疗晚期宫颈癌的标准药物。然而，宫颈癌的分子机制和相关性仍存在不确定性，这有助于优化贝伐单抗的使用。GOG-240 试验中的成本、毒性和方法学问题等因素必须予以考虑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future.

INTRODUCTION The treatment of advanced cervical cancer is continuously developing. There is a critical need to explore new treatment options to improve cure rates and make treatment more affordable. Despite efforts in prevention, cervical cancer remains the fourth most common cancer worldwide in terms of both incidence and mortality. AREAS COVERED This article offers an updated and critical analysis of angiogenesis inhibitors used in the treatment of advanced cervical cancer. It should be noted that this is not a systematic review. EXPERT OPINION Bevacizumab is currently the primary antiangiogenic agent used alongside chemotherapy and has become the standard of care for advanced cervical cancer. However, there are still uncertainties regarding the molecular mechanisms and associations in cervical cancer that could help in optimizing the use of Bevacizumab. Factors such as cost, toxicity, and methodological issues in the GOG-240 trial must be considered.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Opinion on Drug Metabolism & Toxicology 医学-生化与分子生物学

CiteScore

7.90

自引率

2.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The Editors welcome: Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug-drug interactions, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data. Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drug. The audience consists of scientists and managers in the pharmaceutical industry, pharmacologists, clinical toxicologists and related professionals.